APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biodefense

Biodefense market refers to the pharmaceuticals, vaccines and antibodies applied in the treatment of a wide range of infectious diseases, whether those diseases emerge naturally or are deliberately introduced as an act of bioterrorism. Biodefense products generally defense against anthrax, smallpox, botulism, radiation/nuclear disasters and other disasters.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Biodefense market refers to the pharmaceuticals, vaccines and antibodies applied in the treatment of a wide range of infectious diseases, whether those diseases emerge naturally or are deliberately introduced as an act of bioterrorism. Biodefense products generally defense against anthrax, smallpox, botulism, radiation/nuclear disasters and other disasters.

In the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies. Since 2004, the US government has provided assistance in the development and manufacturing of products in order to maintain its Strategic National Stockpile (SNS) to counter any bioterror attack.

Selected research

Market Analysis & Forecast

Global Biodefense Market Analysis and Forecast 2026-2032

2 January 2026206 pages

Choose your research edition.

Industry ResearchBiodefense Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Biodefense Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Biodefense Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biodefense Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Biodefense Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

Biodefense market refers to the pharmaceuticals, vaccines and antibodies applied in the treatment of a wide range of infectious diseases, whether those diseases emerge naturally or are deliberately introduced as an act of bioterrorism. Biodefense products generally defense against anthrax, smallpox, botulism, radiation/nuclear disasters and other disasters.

In the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies. Since 2004, the US government has provided assistance in the development and manufacturing of products in order to maintain its Strategic National Stockpile (SNS) to counter any bioterror attack.

The major players in global Biodefense market include Emergent Biosolutions, Hytest, GSK, etc. The top 3 players occupy about 60% shares of the global market. North America, Europe and Asia are key Regions of Sales. Anthrax and Smallpox are main types, with a share about 70%. US Civilian Market is the main application, which holds a share about 55%.

Read the full market overview

Report Includes

This report presents an overview of global market for Biodefense, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biodefense, also provides the revenue of main regions and countries. Of the upcoming market potential for Biodefense, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biodefense revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biodefense market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Biodefense revenue, projected growth trends, production technology, application and end-user industry.

Biodefense Segment by Company

Emergent Biosolutions

Hytest

GSK

Sanofi

PharmAthene

Bavarian Nordic

SIGA Technologies

Arbutus Biopharma

DynPort Vaccine

Xoma Corporation

Ichor Medical Systems

Aeolus Pharmaceuticals

Achaogen

Elusys Therapeutics

Dynavax Technologies

Cleveland BioLabs

Soligenix

Alnylam Pharmaceuticals

Biodefense Segment by Type

Anthrax

Smallpox

Botulism

Radiation/Nuclear

Others

Biodefense Segment by Application

US Military Market

US Civilian Market

Non - US Market

Biodefense Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biodefense market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biodefense and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biodefense.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Biodefense in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Biodefense company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biodefense revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biodefense Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Anthrax Major Player Table 3. Smallpox Major Player Table 4. Botulism Major Player Table 5. Radiation/Nuclear Major Player Table 6. Others Major Player Table 7. Global Biodefense Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. US Military Market Major Player Table 9. US Civilian Market Major Player Table 10. Non - US Market Major Player Table 11. Biodefense Industry Trends Table 12. Biodefense Industry Drivers Table 13. Biodefense Industry Opportunities and Challenges Table 14. Biodefense Industry Restraints Table 15. Global Biodefense Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Biodefense Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Biodefense Market Share by Region (2021-2026) Table 18. Global Biodefense Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Biodefense Market Share by Region (2027-2032) Table 20. Global Biodefense Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Biodefense Revenue Market Share by Players (2021-2026) Table 22. Global Biodefense Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Biodefense Key Players Headquarters & Area Served Table 24. Global Biodefense Players, Product Type & Application Table 25. Global Biodefense Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Biodefense by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Biodefense Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Biodefense Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Biodefense Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Biodefense Revenue Market Share by Type (2021-2026) Table 32. Global Biodefense Revenue Market Share by Type (2027-2032) Table 33. Global Biodefense Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Biodefense Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Biodefense Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Biodefense Revenue Market Share by Application (2021-2026) Table 37. Global Biodefense Revenue Market Share by Application (2027-2032) Table 38. Emergent Biosolutions Company Information Table 39. Emergent Biosolutions Business Overview Table 40. Emergent Biosolutions Biodefense Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Emergent Biosolutions Biodefense Product Portfolio Table 42. Emergent Biosolutions Recent Development Table 43. Hytest Company Information Table 44. Hytest Business Overview Table 45. Hytest Biodefense Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Hytest Biodefense Product Portfolio Table 47. Hytest Recent Development Table 48. GSK Company Information Table 49. GSK Business Overview Table 50. GSK Biodefense Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. GSK Biodefense Product Portfolio Table 52. GSK Recent Development Table 53. Sanofi Company Information Table 54. Sanofi Business Overview Table 55. Sanofi Biodefense Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Sanofi Biodefense Product Portfolio Table 57. Sanofi Recent Development Table 58. PharmAthene Company Information Table 59. PharmAthene Business Overview Table 60. PharmAthene Biodefense Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. PharmAthene Biodefense Product Portfolio Table 62. PharmAthene Recent Development Table 63. Bavarian Nordic Company Information Table 64. Bavarian Nordic Business Overview Table 65. Bavarian Nordic Biodefense Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Bavarian Nordic Biodefense Product Portfolio Table 67. Bavarian Nordic Recent Development Table 68. SIGA Technologies Company Information Table 69. SIGA Technologies Business Overview Table 70. SIGA Technologies Biodefense Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. SIGA Technologies Biodefense Product Portfolio Table 72. SIGA Technologies Recent Development Table 73. Arbutus Biopharma Company Information Table 74. Arbutus Biopharma Business Overview Table 75. Arbutus Biopharma Biodefense Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Arbutus Biopharma Biodefense Product Portfolio Table 77. Arbutus Biopharma Recent Development Table 78. DynPort Vaccine Company Information Table 79. DynPort Vaccine Business Overview Table 80. DynPort Vaccine Biodefense Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. DynPort Vaccine Biodefense Product Portfolio Table 82. DynPort Vaccine Recent Development Table 83. Xoma Corporation Company Information Table 84. Xoma Corporation Business Overview Table 85. Xoma Corporation Biodefense Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Xoma Corporation Biodefense Product Portfolio Table 87. Xoma Corporation Recent Development Table 88. Ichor Medical Systems Company Information Table 89. Ichor Medical Systems Business Overview Table 90. Ichor Medical Systems Biodefense Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Ichor Medical Systems Biodefense Product Portfolio Table 92. Ichor Medical Systems Recent Development Table 93. Aeolus Pharmaceuticals Company Information Table 94. Aeolus Pharmaceuticals Business Overview Table 95. Aeolus Pharmaceuticals Biodefense Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Aeolus Pharmaceuticals Biodefense Product Portfolio Table 97. Aeolus Pharmaceuticals Recent Development Table 98. Achaogen Company Information Table 99. Achaogen Business Overview Table 100. Achaogen Biodefense Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Achaogen Biodefense Product Portfolio Table 102. Achaogen Recent Development Table 103. Elusys Therapeutics Company Information Table 104. Elusys Therapeutics Business Overview Table 105. Elusys Therapeutics Biodefense Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Elusys Therapeutics Biodefense Product Portfolio Table 107. Elusys Therapeutics Recent Development Table 108. Dynavax Technologies Company Information Table 109. Dynavax Technologies Business Overview Table 110. Dynavax Technologies Biodefense Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Dynavax Technologies Biodefense Product Portfolio Table 112. Dynavax Technologies Recent Development Table 113. Cleveland BioLabs Company Information Table 114. Cleveland BioLabs Business Overview Table 115. Cleveland BioLabs Biodefense Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Cleveland BioLabs Biodefense Product Portfolio Table 117. Cleveland BioLabs Recent Development Table 118. Soligenix Company Information Table 119. Soligenix Business Overview Table 120. Soligenix Biodefense Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Soligenix Biodefense Product Portfolio Table 122. Soligenix Recent Development Table 123. Alnylam Pharmaceuticals Company Information Table 124. Alnylam Pharmaceuticals Business Overview Table 125. Alnylam Pharmaceuticals Biodefense Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Alnylam Pharmaceuticals Biodefense Product Portfolio Table 127. Alnylam Pharmaceuticals Recent Development Table 128. North America Biodefense Revenue by Type (2021-2026) & (US$ Million) Table 129. North America Biodefense Revenue by Type (2027-2032) & (US$ Million) Table 130. North America Biodefense Revenue by Application (2021-2026) & (US$ Million) Table 131. North America Biodefense Revenue by Application (2027-2032) & (US$ Million) Table 132. North America Biodefense Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. North America Biodefense Revenue by Country (2021-2026) & (US$ Million) Table 134. North America Biodefense Revenue by Country (US$ Million) & (2027-2032) Table 135. Europe Biodefense Revenue by Type (2021-2026) & (US$ Million) Table 136. Europe Biodefense Revenue by Type (2027-2032) & (US$ Million) Table 137. Europe Biodefense Revenue by Application (2021-2026) & (US$ Million) Table 138. Europe Biodefense Revenue by Application (2027-2032) & (US$ Million) Table 139. Europe Biodefense Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. Europe Biodefense Revenue by Country (2021-2026) & (US$ Million) Table 141. Europe Biodefense Revenue by Country (US$ Million) & (2027-2032) Table 142. China Biodefense Revenue by Type (2021-2026) & (US$ Million) Table 143. China Biodefense Revenue by Type (2027-2032) & (US$ Million) Table 144. China Biodefense Revenue by Application (2021-2026) & (US$ Million) Table 145. China Biodefense Revenue by Application (2027-2032) & (US$ Million) Table 146. Asia Biodefense Revenue by Type (2021-2026) & (US$ Million) Table 147. Asia Biodefense Revenue by Type (2027-2032) & (US$ Million) Table 148. Asia Biodefense Revenue by Application (2021-2026) & (US$ Million) Table 149. Asia Biodefense Revenue by Application (2027-2032) & (US$ Million) Table 150. Asia Biodefense Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 151. Asia Biodefense Revenue by Region (US$ Million) & (2021-2026) Table 152. Asia Biodefense Revenue by Region (US$ Million) & (2027-2032) Table 153. SAMEA Biodefense Revenue by Type (2021-2026) & (US$ Million) Table 154. SAMEA Biodefense Revenue by Type (2027-2032) & (US$ Million) Table 155. SAMEA Biodefense Revenue by Application (2021-2026) & (US$ Million) Table 156. SAMEA Biodefense Revenue by Application (2027-2032) & (US$ Million) Table 157. SAMEA Biodefense Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 158. SAMEA Biodefense Revenue by Country (2021-2026) & (US$ Million) Table 159. SAMEA Biodefense Revenue by Country (US$ Million) & (2027-2032) Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Biodefense Image Figure 2. Global Biodefense Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biodefense Market Size Share 2021 VS 2025 VS 2032 Figure 4. Anthrax Image Figure 5. Smallpox Image Figure 6. Botulism Image Figure 7. Radiation/Nuclear Image Figure 8. Others Image Figure 9. Global Biodefense Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Biodefense Market Size Share 2021 VS 2025 VS 2032 Figure 11. US Military Market Image Figure 12. US Civilian Market Image Figure 13. Non - US Market Image Figure 14. Global Biodefense Market Size (US$ Million) & (2021-2032) Figure 15. Global Biodefense Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Biodefense Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Biodefense Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Biodefense Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Biodefense Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Biodefense Revenue Market Share by Type (2021-2032) Figure 22. Global Biodefense Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Biodefense Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Biodefense Revenue Market Share by Application (2021-2032) Figure 25. North America Biodefense Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Biodefense Revenue Share by Type (2021-2032) Figure 27. North America Biodefense Revenue Share by Application (2021-2032) Figure 28. North America Biodefense Revenue Share by Country (2021-2032) Figure 29. United States Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Biodefense Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Biodefense Revenue Share by Type (2021-2032) Figure 34. Europe Biodefense Revenue Share by Application (2021-2032) Figure 35. Europe Biodefense Revenue Share by Country (2021-2032) Figure 36. Germany Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Biodefense Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Biodefense Revenue Share by Type (2021-2032) Figure 46. China Biodefense Revenue Share by Application (2021-2032) Figure 47. Asia Biodefense Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Biodefense Revenue Share by Type (2021-2032) Figure 49. Asia Biodefense Revenue Share by Application (2021-2032) Figure 50. Asia Biodefense Revenue Share by Region (2021-2032) Figure 51. Japan Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Biodefense Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Biodefense Revenue Share by Type (2021-2032) Figure 59. SAMEA Biodefense Revenue Share by Application (2021-2032) Figure 60. SAMEA Biodefense Revenue Share by Country (2021-2032) Figure 61. Brazil Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Biodefense Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Anthrax
  • Smallpox
  • Botulism
  • Radiation/Nuclear
  • Others
Applications
  • US Military Market
  • US Civilian Market
  • Non - US Market
Companies covered
  • Emergent Biosolutions
  • Hytest
  • GSK
  • Sanofi
  • PharmAthene
  • Bavarian Nordic
  • SIGA Technologies
  • Arbutus Biopharma
  • DynPort Vaccine
  • Xoma Corporation
  • Ichor Medical Systems
  • Aeolus Pharmaceuticals
  • Achaogen
  • Elusys Therapeutics
  • Dynavax Technologies
  • Cleveland BioLabs
  • Soligenix
  • Alnylam Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Biodefense Market by Type
  3. 1.2.1 Global Biodefense Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Anthrax
  5. 1.2.3 Smallpox
  6. 1.2.4 Botulism
  7. 1.2.5 Radiation/Nuclear
  8. 1.2.6 Others
  9. 1.3 Biodefense Market by Application
  10. 1.3.1 Global Biodefense Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 US Military Market
  12. 1.3.3 US Civilian Market
  13. 1.3.4 Non - US Market
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Biodefense Market Dynamics
  1. 2.1 Biodefense Industry Trends
  2. 2.2 Biodefense Industry Drivers
  3. 2.3 Biodefense Industry Opportunities and Challenges
  4. 2.4 Biodefense Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Biodefense Market Perspective (2021-2032)
  2. 3.2 Global Biodefense Growth Trends by Region
  3. 3.2.1 Global Biodefense Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Biodefense Market Size by Region (2021-2026)
  5. 3.2.3 Global Biodefense Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Biodefense Revenue by Players
  2. 4.1.1 Global Biodefense Revenue by Players (2021-2026)
  3. 4.1.2 Global Biodefense Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Biodefense Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Biodefense Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Biodefense Key Players Headquarters & Area Served
  7. 4.4 Global Biodefense Players, Product Type & Application
  8. 4.5 Global Biodefense Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Biodefense Market CR5 and HHI
  11. 4.6.3 2025 Biodefense Tier 1, Tier 2, and Tier 3
5 Biodefense Market Size by Type
  1. 5.1 Global Biodefense Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Biodefense Revenue by Type (2021-2032)
  3. 5.3 Global Biodefense Revenue Market Share by Type (2021-2032)
6 Biodefense Market Size by Application
  1. 6.1 Global Biodefense Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Biodefense Revenue by Application (2021-2032)
  3. 6.3 Global Biodefense Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Emergent Biosolutions
  2. 7.1.1 Emergent Biosolutions Company Information
  3. 7.1.2 Emergent Biosolutions Business Overview
  4. 7.1.3 Emergent Biosolutions Biodefense Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Emergent Biosolutions Biodefense Product Portfolio
  6. 7.1.5 Emergent Biosolutions Recent Developments
  7. 7.2 Hytest
  8. 7.2.1 Hytest Company Information
  9. 7.2.2 Hytest Business Overview
  10. 7.2.3 Hytest Biodefense Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Hytest Biodefense Product Portfolio
  12. 7.2.5 Hytest Recent Developments
  13. 7.3 GSK
  14. 7.3.1 GSK Company Information
  15. 7.3.2 GSK Business Overview
  16. 7.3.3 GSK Biodefense Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GSK Biodefense Product Portfolio
  18. 7.3.5 GSK Recent Developments
  19. 7.4 Sanofi
  20. 7.4.1 Sanofi Company Information
  21. 7.4.2 Sanofi Business Overview
  22. 7.4.3 Sanofi Biodefense Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sanofi Biodefense Product Portfolio
  24. 7.4.5 Sanofi Recent Developments
  25. 7.5 PharmAthene
  26. 7.5.1 PharmAthene Company Information
  27. 7.5.2 PharmAthene Business Overview
  28. 7.5.3 PharmAthene Biodefense Revenue and Gross Margin (2021-2026)
  29. 7.5.4 PharmAthene Biodefense Product Portfolio
  30. 7.5.5 PharmAthene Recent Developments
  31. 7.6 Bavarian Nordic
  32. 7.6.1 Bavarian Nordic Company Information
  33. 7.6.2 Bavarian Nordic Business Overview
  34. 7.6.3 Bavarian Nordic Biodefense Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bavarian Nordic Biodefense Product Portfolio
  36. 7.6.5 Bavarian Nordic Recent Developments
  37. 7.7 SIGA Technologies
  38. 7.7.1 SIGA Technologies Company Information
  39. 7.7.2 SIGA Technologies Business Overview
  40. 7.7.3 SIGA Technologies Biodefense Revenue and Gross Margin (2021-2026)
  41. 7.7.4 SIGA Technologies Biodefense Product Portfolio
  42. 7.7.5 SIGA Technologies Recent Developments
  43. 7.8 Arbutus Biopharma
  44. 7.8.1 Arbutus Biopharma Company Information
  45. 7.8.2 Arbutus Biopharma Business Overview
  46. 7.8.3 Arbutus Biopharma Biodefense Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Arbutus Biopharma Biodefense Product Portfolio
  48. 7.8.5 Arbutus Biopharma Recent Developments
  49. 7.9 DynPort Vaccine
  50. 7.9.1 DynPort Vaccine Company Information
  51. 7.9.2 DynPort Vaccine Business Overview
  52. 7.9.3 DynPort Vaccine Biodefense Revenue and Gross Margin (2021-2026)
  53. 7.9.4 DynPort Vaccine Biodefense Product Portfolio
  54. 7.9.5 DynPort Vaccine Recent Developments
  55. 7.10 Xoma Corporation
  56. 7.10.1 Xoma Corporation Company Information
  57. 7.10.2 Xoma Corporation Business Overview
  58. 7.10.3 Xoma Corporation Biodefense Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Xoma Corporation Biodefense Product Portfolio
  60. 7.10.5 Xoma Corporation Recent Developments
  61. 7.11 Ichor Medical Systems
  62. 7.11.1 Ichor Medical Systems Company Information
  63. 7.11.2 Ichor Medical Systems Business Overview
  64. 7.11.3 Ichor Medical Systems Biodefense Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Ichor Medical Systems Biodefense Product Portfolio
  66. 7.11.5 Ichor Medical Systems Recent Developments
  67. 7.12 Aeolus Pharmaceuticals
  68. 7.12.1 Aeolus Pharmaceuticals Company Information
  69. 7.12.2 Aeolus Pharmaceuticals Business Overview
  70. 7.12.3 Aeolus Pharmaceuticals Biodefense Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Aeolus Pharmaceuticals Biodefense Product Portfolio
  72. 7.12.5 Aeolus Pharmaceuticals Recent Developments
  73. 7.13 Achaogen
  74. 7.13.1 Achaogen Company Information
  75. 7.13.2 Achaogen Business Overview
  76. 7.13.3 Achaogen Biodefense Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Achaogen Biodefense Product Portfolio
  78. 7.13.5 Achaogen Recent Developments
  79. 7.14 Elusys Therapeutics
  80. 7.14.1 Elusys Therapeutics Company Information
  81. 7.14.2 Elusys Therapeutics Business Overview
  82. 7.14.3 Elusys Therapeutics Biodefense Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Elusys Therapeutics Biodefense Product Portfolio
  84. 7.14.5 Elusys Therapeutics Recent Developments
  85. 7.15 Dynavax Technologies
  86. 7.15.1 Dynavax Technologies Company Information
  87. 7.15.2 Dynavax Technologies Business Overview
  88. 7.15.3 Dynavax Technologies Biodefense Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Dynavax Technologies Biodefense Product Portfolio
  90. 7.15.5 Dynavax Technologies Recent Developments
  91. 7.16 Cleveland BioLabs
  92. 7.16.1 Cleveland BioLabs Company Information
  93. 7.16.2 Cleveland BioLabs Business Overview
  94. 7.16.3 Cleveland BioLabs Biodefense Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Cleveland BioLabs Biodefense Product Portfolio
  96. 7.16.5 Cleveland BioLabs Recent Developments
  97. 7.17 Soligenix
  98. 7.17.1 Soligenix Company Information
  99. 7.17.2 Soligenix Business Overview
  100. 7.17.3 Soligenix Biodefense Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Soligenix Biodefense Product Portfolio
  102. 7.17.5 Soligenix Recent Developments
  103. 7.18 Alnylam Pharmaceuticals
  104. 7.18.1 Alnylam Pharmaceuticals Company Information
  105. 7.18.2 Alnylam Pharmaceuticals Business Overview
  106. 7.18.3 Alnylam Pharmaceuticals Biodefense Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Alnylam Pharmaceuticals Biodefense Product Portfolio
  108. 7.18.5 Alnylam Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Biodefense Revenue (2021-2032)
  2. 8.2 North America Biodefense Revenue by Type (2021-2032)
  3. 8.2.1 North America Biodefense Revenue by Type (2021-2026)
  4. 8.2.2 North America Biodefense Revenue by Type (2027-2032)
  5. 8.3 North America Biodefense Revenue Share by Type (2021-2032)
  6. 8.4 North America Biodefense Revenue by Application (2021-2032)
  7. 8.4.1 North America Biodefense Revenue by Application (2021-2026)
  8. 8.4.2 North America Biodefense Revenue by Application (2027-2032)
  9. 8.5 North America Biodefense Revenue Share by Application (2021-2032)
  10. 8.6 North America Biodefense Revenue by Country
  11. 8.6.1 North America Biodefense Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Biodefense Revenue by Country (2021-2026)
  13. 8.6.3 North America Biodefense Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Biodefense Revenue (2021-2032)
  2. 9.2 Europe Biodefense Revenue by Type (2021-2032)
  3. 9.2.1 Europe Biodefense Revenue by Type (2021-2026)
  4. 9.2.2 Europe Biodefense Revenue by Type (2027-2032)
  5. 9.3 Europe Biodefense Revenue Share by Type (2021-2032)
  6. 9.4 Europe Biodefense Revenue by Application (2021-2032)
  7. 9.4.1 Europe Biodefense Revenue by Application (2021-2026)
  8. 9.4.2 Europe Biodefense Revenue by Application (2027-2032)
  9. 9.5 Europe Biodefense Revenue Share by Application (2021-2032)
  10. 9.6 Europe Biodefense Revenue by Country
  11. 9.6.1 Europe Biodefense Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Biodefense Revenue by Country (2021-2026)
  13. 9.6.3 Europe Biodefense Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Biodefense Revenue (2021-2032)
  2. 10.2 China Biodefense Revenue by Type (2021-2032)
  3. 10.2.1 China Biodefense Revenue by Type (2021-2026)
  4. 10.2.2 China Biodefense Revenue by Type (2027-2032)
  5. 10.3 China Biodefense Revenue Share by Type (2021-2032)
  6. 10.4 China Biodefense Revenue by Application (2021-2032)
  7. 10.4.1 China Biodefense Revenue by Application (2021-2026)
  8. 10.4.2 China Biodefense Revenue by Application (2027-2032)
  9. 10.5 China Biodefense Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Biodefense Revenue (2021-2032)
  2. 11.2 Asia Biodefense Revenue by Type (2021-2032)
  3. 11.2.1 Asia Biodefense Revenue by Type (2021-2026)
  4. 11.2.2 Asia Biodefense Revenue by Type (2027-2032)
  5. 11.3 Asia Biodefense Revenue Share by Type (2021-2032)
  6. 11.4 Asia Biodefense Revenue by Application (2021-2032)
  7. 11.4.1 Asia Biodefense Revenue by Application (2021-2026)
  8. 11.4.2 Asia Biodefense Revenue by Application (2027-2032)
  9. 11.5 Asia Biodefense Revenue Share by Application (2021-2032)
  10. 11.6 Asia Biodefense Revenue by Country
  11. 11.6.1 Asia Biodefense Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Biodefense Revenue by Country (2021-2026)
  13. 11.6.3 Asia Biodefense Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Biodefense Revenue (2021-2032)
  2. 12.2 SAMEA Biodefense Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Biodefense Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Biodefense Revenue by Type (2027-2032)
  5. 12.3 SAMEA Biodefense Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Biodefense Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Biodefense Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Biodefense Revenue by Application (2027-2032)
  9. 12.5 SAMEA Biodefense Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Biodefense Revenue by Country
  11. 12.6.1 SAMEA Biodefense Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Biodefense Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Biodefense Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst